A $3.08 Billion Perspective on Chromatography Media in 2026: A New Global Market Landscape Shaped by Monoclonal Antibodies, the Rise of Peptides, and Accelerating Domestic Substitution [Infographic]

Table of Contents Table of Contents 1. Market Overview 1.1 Definition and Classification of Chromatography Media 1.2 Global Chromatography Media Market Size and Forecast 1.2.1 Global Chromatography Media Market Size (by Revenue), 2021–2032 1.2.2 Global Chromatography Media Market Size (by Volume), 2021–2032 1.2.3 Global Chromatography Media Price Trends, 2021–2032 1.3 China’s Chromatography Media Market Size and Forecast 1.3.1 China’s Chromatography Media Market Size (by Revenue), 2021–2032 1.3.2 China’s Chromatography Media Market Size (by Volume), 2021–2032 1.3.3 China’s Chromatography Media Price Trends, 2021–2032 1.4 Analysis of China’s Position in the Global Market 1.4.1 China’s Share of the Global Chromatography Media Market (by Revenue), 2021–2032 1.4.2 China’s Share of the Global Chromatography Media Market (by Volume), 2021–2032 1.4.3 Comparison of China’s and the Global Chromatography Media Market Growth Rates, 2021–2032 1.5 Analysis of Industry Opportunities, Challenges, Trends, and Policies 1.5.1 Drivers and Opportunities in the Chromatography Media Industry 1.5.2 Constraints and Challenges Facing the Chromatography Media Industry 1.5.3 Development Trends in the Chromatography Media Industry 1.5.4 Policy Analysis of Related Industries in the Chinese Market 2. Market Share and Rankings of Global Leading Manufacturers 2.1 Global Leading Manufacturers’ Market Share (by Chromatography Media Revenue), 2021–2026 2.2 Global Leading Manufacturers’ Market Share (by Chromatography Media Volume), 2021–2026 2.3 Price Comparison Among Global Leading Manufacturers, 2021–2026 2.4 Analysis of Three Tiers of Chromatography Media Market Participants: Global First-Tier, Second-Tier, and Third-Tier Players 2.5 Concentration Analysis of the Global Chromatography Media Industry 2.6 M&A Activity in the Global Chromatography Media Industry 2.7 Product Listings of Leading Global Chromatography Media Manufacturers 2.8 Headquarters and Production Locations of Major Global Manufacturers 2.9 Recent Chromatography Media Capacity Changes and Future Plans of Key Global Producers 3. Market Share and Rankings of Leading Chinese Manufacturers 3.1 Market Share of Leading Chinese Manufacturers (by Chromatography Media Revenue), 2021–2026 3.2 Market Share of Leading Chinese Manufacturers (by Chromatography Media Volume), 2021–2026 3.3 Market Share Distribution Among Chinese Chromatography Media Participants: First-Tier, Second-Tier, and Third-Tier Players 4. Capacity and Output Analysis Across Major Global Regions 4.1 Global Chromatography Media Industry Total Capacity, Output, and Capacity Utilization Rate, 2021–2032 4.2 Chromatography Media Capacity Analysis by Major Global Region 4.3 Chromatography Media Output and Future Growth Forecasts by Major Global Region, 2021 vs. 2025 vs. 2032 4.4 Chromatography Media Output by Major Global Production Regions, 2021–2032 4.5 Chromatography Media Output Share by Major Global Production Regions, 2021–2032

2026 Pharmaceutical Industry Barometer: Ecolab Executive Reveals Three Life-or-Death Battles for Cost Reduction and Efficiency Enhancement—AI and Continuous Manufacturing as Decisive Factors

Introduction: Amid the dual pressures of patent cliffs and global cost-containment efforts, the rules of pharmaceutical manufacturing are being fundamentally rewritten. Top industry experts state unequivocally: In 2026, reducing production costs is no longer an option—it is a life-or-death battle for survival. Who will win this war? The answer lies in AI, continuous manufacturing, and a profound revolution in supply chain relationships. I. Core Insight: In 2026, Everything Revolves Around “Cost” Laine Mello, Ecolab’s Director of Bioprocess Markets, states clearly: “Reducing production costs” will be the undisputed top priority for bioprocessing in 2026. The reason is stark: pricing pressure on complex biologics has reached its limit, forcing companies to extract efficiency from every single step of production. This means: • Continuous manufacturing will shift from pioneering pilot projects to standard practice. • Process intensification (e.g., high-capacity chromatography) will no longer be an optimization option—but a fundamental profitability threshold. • Modular facilities will become essential tools for responding to market volatility. II. Three Technological Engines Driving the Productivity Revolution 1. AI: From “Support Tool” to “Decision-Making Core” • R&D Side: AI has compressed new molecular design cycles from “months” to “weeks,” completely transforming the starting line for novel drug discovery. • Production Side: Predictive maintenance is eliminating batch failures; real-time quality analytics enable lightning-fast release decisions. AI removes “uncertainty” from manufacturing processes, clearing the biggest obstacle to continuous manufacturing. Mello states bluntly: “Digital technologies have shifted from ‘nice-to-have’ to a comprehensive race where hesitation equals falling behind. By 2025, hesitant enterprises were already forced into full-speed catch-up.” 2. Continuous Manufacturing: A Dual “Paradigm Shift” in Efficiency and Quality This is not merely about “going faster”—it is a complete reconstruction of the entire production logic. • Data Evidence: Real-world cases show continuous manufacturing can shorten production cycles by 30%–40%, while simultaneously improving product consistency. • Fundamental Transformation: It redefines the foundational principles of quality control and process scale-up, unlocking optimization spaces inaccessible to traditional batch production. 3. Sustainability: From “Cost Center” to “Profit Center” The pivotal shift in 2025 is that energy and water conservation are no longer pursued solely for regulatory compliance or corporate image. • New Mindset: Reducing water and energy consumption directly boosts profits and strengthens operational resilience. • New Positioning: Sustainability has become a tangible competitive advantage and a genuine business moat.

Ecolab Inc Executive Files Form 4 Disclosure

Nov 5, 2026

Ecolab Inc submitted a Form 4 filing regarding insider stock transactions by EVP Benjamin M. Clark on November 2nd, with specific transaction details not provided in the report.

Investing.com Canada

2026-07-09

Basic Materials: Sector Rises but Underperforms, Leaving Opportunities in Chemicals and Agriculture

2026-10-03

Director Acquires 131.17 Shares at $0 Each Through Ecolab Stock Award

2026-10-13

Ecolab Director David MacLennan Files Form 4 on September 30

2026-11-05

Ecolab Inc Executive Files Form 4 Disclosure

Ecolab Inc Executive Files Form 4 Disclosure

FAQ